Aptar Pharma receives FDA approval for nasal device for depression

Drug delivery systems provider Aptar Pharma, has announced that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression.

This marks the first FDA approval and U.S. launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.

This customised Bidose liquid device is produced in Aptar Pharma’s manufacturing facility in Congers, New York, which offers laboratory and other organisational capabilities to support nasal and injectable drug delivery systems. The system is designed for local or systemic delivery of drugs.

Gael Touya, president of Aptar Pharma said: “We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression. This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”